162
Participants
Start Date
January 16, 2024
Primary Completion Date
February 24, 2025
Study Completion Date
February 24, 2025
Nitric Oxide Releasing Solution
The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
Nasal spray with isotonic saline
The Sponsor designed a dual-chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
Okanegan Clinical Trials, Kelowna
Richmond Clinical Trials (Okanagan Clinical Trials Satelite Site), Richmond
Cliantha Research, Mississauga
Clinical Research of Ontario, Scarborough Village
Intermed Groupe Santé, Chicoutimi
Alpha Recherche Clinique LeBourneuf, Québec
Alpha Recherche Clinique Val-Belair, Québec
Sanotize Research and Development corp.
INDUSTRY